Contraindications for the lung cancer targeted drug capmatinib (capatinib)

Capmatinib (Capmatinib) is a drug used to treat people with the MET gene14 Targeted drugs for advanced or metastatic non-small cell lung cancer (NSCLC) with exon skipping mutations (METex14). Although capmatinib (capatinib) has shown significant efficacy in treating patients with these specific types of lung cancer, there are some contraindications and precautions that need to be noted when using it to ensure patient safety and therapeutic efficacy. The following is a detailed description of the contraindications and related precautions for Capatinib.

1. Known allergy to capmatinib or any of its ingredients

This medication should not be used in patients who are allergic to capmatinib or any of its excipients. Allergic reactions may include rash, itching, difficulty breathing, facial swelling and other serious reactions. Once an allergic reaction occurs, the medication should be stopped immediately and appropriate therapeutic intervention should be carried out.

2. Severe liver insufficiency

Capmatinib is metabolized by the liver, so patients with severe hepatic impairment may experience accumulation of the drug, leading to increased drug toxicity. Such patients need to be particularly cautious when using capmatinib (capatinib), and a dose reduction or other treatment options should usually be considered. Liver function tests should be performed before and regularly during medication to monitor changes in liver function.

3. Severe renal insufficiency

Althoughcapatinib (capatinib) is primarily metabolized by the liver, this drug should also be used with caution in patients with severe renal impairment. Such patients may require dose adjustments and close monitoring of renal function during treatment. Proper dose adjustment and monitoring can help reduce the potential toxicity of the drug.

4. Pregnant and lactating women

Capmatinib may cause harm to a fetus, so this drug should not be used by pregnant women or women who may become pregnant. Effective contraceptive measures should be used during treatment to avoid pregnancy. If pregnancy is discovered during treatment, the doctor should be informed immediately and the pros and cons of continuing the medication should be discussed.

For breastfeeding women, it is not known whether capmatinib is passed into breast milk. Therefore, to avoid potential risks to the infant, it is recommended that breastfeeding be discontinued while taking capmatinib.

5.Patients with QTinterval prolongation

Capmatinib may cause QT interval prolongation, increasing the risk of cardiac arrhythmias. Therefore, capmatinib (capatinib) should be used with caution in patients with a known history of QT prolongation or in patients taking other drugs that may cause QT prolongation. During treatment, patients should undergo regular electrocardiograms to monitor changes inQTinterval.

6. Patients with interstitial lung disease

Capmatinib may cause interstitial lung disease or pneumonia, which may be manifested by symptoms such as difficulty breathing, cough, and fever. Capmatinib (capatinib) should be used with caution in patients with a history of interstitial lung disease or pneumonia. During treatment, once the above symptoms occur, the drug should be discontinued immediately and detailed pulmonary evaluation and treatment should be performed.

7. Drug interactions

Capatinib may interact with certain drugs, affecting their efficacy or increasing the risk of adverse reactions. Here are some medications that require special attention:

StrongCYP3A4inhibitors: such as ketoconazole, itraconazole, etc., may increase the plasma concentration of capmatinib (capatinib) , thereby increasing drug toxicity.

StrongCYP3A4inducers: such as rifampicin, St. John's wort, etc., may reduce the plasma concentration of capatinib (capatinib) , thus reducing its efficacy.

P-gpinhibitors: such as verapamil, cyclosporine, etc., may increase the absorption and toxicity of capatinib (capatinib).

8. Elderly patients

Elderly patients (65 years and above) may have increased sensitivity tocapatinib (capatinib) and are often associated with other chronic diseases. Special attention should be paid to dosage adjustment and monitoring of adverse reactions.

9. Children and Adolescents

There are limited data on the safety and efficacy of capmatinib in children and adolescents and its use is not recommended in patients 18 years of age.

10. Diet and lifestyle considerations

Patients should pay attention to dietary and lifestyle adjustments while taking Capatinib to reduce adverse reactions and enhance drug efficacy. For example, avoid foods rich in vitamin K (such as green leafy vegetables), which may affect drug metabolism. Maintaining good living habits and avoiding smoking and excessive drinking can also help reduce adverse drug reactions.

As an effective targeted therapy for lung cancer, capmatinib requires special attention to its contraindications and related precautions when using it. Allergies to Capatinib (Capatinib) or its ingredients, severe hepatic and renal insufficiency, pregnant and lactating women, patients with QT prolongation, patients with interstitial lung disease, and situations where drug interactions need to be considered are all aspects that require special attention. During clinical use, medical staff should conduct comprehensive assessment and monitoring of patients to ensure the safety and effectiveness of treatment. Patients should also closely cooperate with their doctors during medication and undergo regular examinations and follow-up visits to obtain the best therapeutic effect.